Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Jeffrey Crowley, Diamant Thaçi, P. Joly, et al.
Journal of the American Academy of Dermatology (2017) Vol. 77, Iss. 2, pp. 310-317.e1
Open Access | Times Cited: 168

Showing 26-50 of 168 citing articles:

Off-label studies on apremilast in dermatology: a review
Nolan J. Maloney, Jeffrey Zhao, Kyle Tegtmeyer, et al.
Journal of Dermatological Treatment (2019) Vol. 31, Iss. 2, pp. 131-140
Open Access | Times Cited: 42
Small molecule therapy for managing moderate to severe psoriatic arthritis
Luisa Costa, Antonio Del Puente, Rosario Peluso, et al.
Expert Opinion on Pharmacotherapy (2017) Vol. 18, Iss. 15, pp. 1557-1567
Closed Access | Times Cited: 41
Apremilast is effective in controlling the progression of adult vitiligo: A case series
Imran Majid, Saher Imran, Sameena Batool
Dermatologic Therapy (2019), pp. e12923-e12923
Open Access | Times Cited: 39
New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis.
Corinna Eleni Psomadakis, George Han
PubMed (2019) Vol. 12, Iss. 12, pp. 28-34
Closed Access | Times Cited: 38
Cancer risk in patients with psoriasis: should we be paying more attention?
Nikolai Loft, Sofie Vaengebjerg, Lone Skov
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 5, pp. 479-492
Closed Access | Times Cited: 38
The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic
Yu Ri Woo, Chul Jong Park, Hoon Kang, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7041-7041
Open Access | Times Cited: 38
Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 1)
Jo Lambert, Siegfried Segaert, Pierre‐Dominique Ghislain, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 8, pp. 1654-1665
Open Access | Times Cited: 37
Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast
Davide Fattore, Maria Carmela Annunziata, Luigia Panariello, et al.
European Journal of Cancer (2019) Vol. 110, pp. 107-109
Closed Access | Times Cited: 36
Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)
Jo Lambert, Siegfried Segaert, Pierre‐Dominique Ghislain, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 9, pp. 1914-1923
Open Access | Times Cited: 34
Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists
Omid Zahedi Niaki, Milan J. Anadkat, Steven T. Chen, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 4, pp. 1150-1159
Open Access | Times Cited: 33
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial
Joseph F. Merola, Lawrence Charles Parish, Lyn Guenther, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 3, pp. 485-493
Open Access | Times Cited: 11
Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus
Tiago Torres, Nicolò Costantino Brembilla, Richard Langley, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 4
Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits.
Daniela Mikhaylov, Peter W. Hashim, Tatyana Nektalova, et al.
PubMed (2019) Vol. 12, Iss. 6, pp. 46-54
Closed Access | Times Cited: 32
Safety concerns with current treatments for psoriasis in the elderly
Roberta Di Caprio, Giuseppina Caiazzo, Sara Cacciapuoti, et al.
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 4, pp. 523-531
Closed Access | Times Cited: 32
Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases
Tarun Narang, Akanksha Kaushik, Sunil Dogra
British Journal of Dermatology (2019) Vol. 182, Iss. 4, pp. 1034-1037
Closed Access | Times Cited: 30
Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis
Chun‐Hsien Huang, I‐Hsin Huang, Cheng‐Chen Tai, et al.
Biomedicines (2022) Vol. 10, Iss. 6, pp. 1303-1303
Open Access | Times Cited: 19
Gender-related Therapeutical Response to Apremilast: New Insights in a Tailored Management of Psoriasis
Emanuele Trovato, Federico Bardazzi, Vito Di Lernia, et al.
Dermatology Practical & Conceptual (2025) Vol. 15, Iss. 1, pp. 4805-4805
Open Access
Probing the dark chemical matter against PDE4 for the management of psoriasis using in silico, in vitro and in vivo approach
B Swapna, Satvik Kotha, S. Divakar, et al.
Molecular Diversity (2025)
Closed Access
Dialkyloxyphenyl hybrids as PDE4B inhibitors: Design, synthesis, in vitro/in vivo anti-inflammatory activity and in silico insights
Aya M. Almatary, Mohamed S. H. Salem, Mohamed R. Elnagar, et al.
Bioorganic Chemistry (2025), pp. 108511-108511
Closed Access
Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
Y. Xu, X LIU, Linghong Guo, et al.
Clinical Cosmetic and Investigational Dermatology (2025) Vol. Volume 18, pp. 1121-1135
Open Access
Recomendaciones de la Sociedad Española de Reumatología sobre el tratamiento y uso de terapias sistémicas biológicas y no biológicas en artritis psoriásica
Juan Carlos Torre Alonso, Petra Díaz del Campo Fontecha, Raquel Almodóvar, et al.
Reumatología Clínica (2017) Vol. 14, Iss. 5, pp. 254-268
Closed Access | Times Cited: 33
Immune mediators and therapies for pruritus in atopic dermatitis and psoriasis
Sebastian Yu, Yanxi Li, Yan Zhou, et al.
Journal of Cutaneous Immunology and Allergy (2019) Vol. 2, Iss. 1, pp. 4-14
Open Access | Times Cited: 27
Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
Jia C. Gao, Albert G. Wu, Marissa Contento, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 395-402
Open Access | Times Cited: 16
Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience
Prisca Guerra, Antonella Di Cesare, Elia Rosi, et al.
Life (2024) Vol. 14, Iss. 3, pp. 395-395
Open Access | Times Cited: 3
Long‐term effectiveness and tolerability of apremilast in patients with moderate‐to‐severe plaque psoriasis: A 5‐year multicentre retrospective study—IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 11
Closed Access | Times Cited: 3

Scroll to top